image

Subsidiaries

Blazing a New Path in Medicine

Nurix is committed to bringing novel, first-in-class therapies to patients without adequate treatment options. Our small molecule drugs are designed to modulate protein levels in cells as a new therapeutic approach for a broad range of diseases.

Nurix was founded by a team of internationally renowned scientific experts in the fields of E3 ubiquitin ligase regulation and structure. Since its incorporation, Nurix has built a seasoned team of leaders with wide-ranging backgrounds in both small molecule drug development and adoptive cell therapy. Through its leadership in Targeted Protein Degradation and its powerful proprietary DELigase platform, Nurix has attracted world leading partners including its current drug discovery collaborations with Sanofi and Gilead Sciences.

DeCART Therapeutics

DeCART Therapeutics is a biotechnology company founded by Nurix and a team of scientific and business leaders from the University of Pennsylvania, including Carl H. June, M.D., Joseph A. Fraietta, Ph.D., Xianxin Hua, M.D., Ph.D., and Dana M. Hammill, M.S., M.B.A. Enhancing CAR T cells with small molecule targeted protein modulation is the scientific foundation of DeCART, which stands for drug-enhanced CAR T cells.